CYP3A4 and acute kidney injury: Although the incidence of AKI was not increased after monotherapy of lopinavir/ritonavir in COVID-19 patients in a randomized-controlled study [72], Schneider et al. announced that combining antiviral agents metabolized by CYP3A4 with HCQ is significantly associated with a higher incidence of AKI [70].